J&J HIV therapy approved by the US FDA for use in children
A HIV antiretroviral therapy, EDURANT®, from Johnson & Johnson has been granted approval from the US FDA for use in children with HIV-1 from the age of two.
HIV represents a huge burden on public health across the globe. In 2022 it was estimated that 39 million people were living with HIV, with the majority of those in Africa, and 2.58 million made up of children aged between 0 and 19 years old.
Now, the US FDA has approved the antiretroviral treatment EDURANT® PED (rilpivirine) from Johnson & Johnson for children. The therapy is used to HIV-1 in combination with other antiretroviral therapies in treatment naïve children, weighing between 14 and 25 kg.
J&J have pioneered HIV/AIDS treatment and aid since 1985, working with several charities and bodies to help those suffering across the world and give access to a range of treatment options that could help them. EDURANT® was initially approved in 2011, and after much testing and research J&J are pleased to announce the approval in paediatric patients with the disease.
“Decades of experience with the global HIV epidemic have made it clear that new and improved treatment options are needed to support the diverse population of people living with HIV on their treatment journey,” stated Penny Heaton, MD, Global Therapeutic Area Head, Infectious Diseases and Vaccines at Johnson & Johnson. “While the population of young children living with HIV is small, additional treatment options remain key to ensuring that each person living with HIV can be matched to a treatment regimen that is right for them.”
The approval comes after results from two clinical trials were released from J&J. The PAINT and PICTURE studies looked at paediatric patients, who were treated with rilpivirine in conjunction with other antiretrovirals. The results of the studies demonstrated that rilpivirine was effective in suppressing the HIV-1 virus in patients with HIV-1 RNA <100,000 copies/mL.
The dosing has been updated to include not only a 25 mg oral dosage (EDURANT®) but also a weight adjusted oral tablet of 2.5 mg, which is more suitable for children.
Source:
Johnson & Johnson. U.S. FDA Approves EDURANT® PED (rilpivirine) for Certain Pediatric Patients Living with HIV-1. [Date accessed]. www.jnj.com/media-center/press-releases/u-s-fda-approves-edurant-ped-rilpivirine-for-certain-pediatric-patients-living-with-hiv-1
Related News
-
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News First look at the Start-Up companies featuring at CPHI North America 2024
In the following infographic, the first five Start-Up companies that are exhibiting at the brand new Start-Up Market at CPHI North America this May, are showcased. Hear from the Start-Ups themselves on what they are most looking forward to at the show.... -
News Novo Nordisk gains expanded approval for Wegovy to treat heart failure
Wegovy, the blockbuster weight loss drug from Danish drugmaker Novo Nordisk has now received expanded approval from the US FDA for use in the prevention of stroke and heart attacks. -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Coronary drug-coated medical device receives US FDA approval
Boston Scientific announced the FDA approval of their medical device AGENT Drug-Coated Balloon (DCB) for the indication of coronary in-stent restenosis in coronary artery disease patients. -
News Global advancements in the diagnosis and treatment of rare diseases: Rare Disease Day 2024
Rare Diseases Day is celebrated on the 29th February 2024 and represents the plight of rare disease patients to gain diagnosis and access to suitable treatment. -
News CPHI Online Webinar Series – Innovative Strategies for B2B Pharma Marketeers
On February 20, 2024, CPHI Online hosted a webinar on Innovative Strategies for B2B Pharma Marketeers. Featuring expert speakers from across the pharmaceutical value chain, this webinar delves into how B2B pharma marketeers can create better content to... -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance